(OMED) and Celgene Announce Strategic Collaboration

Celgene Invests in OncoMed’s Demcizumab and up to Five Additional Preclinical Biologics Programs; OncoMed Leads Early Clinical Trials and Retains Co-Development, Co-Commercialization and Profit-Sharing Rights

OncoMed to Receive $177.25 Million Upfront, Including a $22.25 Million Equity Investment

OncoMed to Host a Conference Call This Morning for Investors at 8:30 a.m. ET

REDWOOD CITY, Calif., Dec. 3, 2013 — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) and Celgene Corporation (Nasdaq:CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed’s biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).

OncoMed will control and conduct initial clinical studies at which point Celgene has an option to license worldwide rights to up to six novel anti-CSC therapeutic candidates. OncoMed retains global co-development and U.S. co-commercialization rights for five of the six anti-CSC product candidates with 50/50 U.S. profit sharing, and royalties to be received in other territories. Celgene will also have research, development and commercialization rights to small molecule compounds in an undisclosed cancer stem cell pathway.

Celgene obtains an exclusive option on one of OncoMed’s most advanced clinical candidates, demcizumab, during or after the completion of certain future planned Phase II clinical trials to be conducted by OncoMed. Demcizumab is currently in three Phase Ib clinical studies in combination with standard-of-care therapeutics, including a trial in patients with first-line advanced pancreatic cancer. Subsequent to option exercise, the parties will co-develop demcizumab, sharing global development costs on a 1/3 OncoMed and 2/3 Celgene basis. The companies will co-commercialize demcizumab in the United States with 50/50 profit sharing. Outside the United States, Celgene would lead development and commercialization, with OncoMed eligible to receive milestones and tiered double-digit royalties on sales outside the United States.

In addition to demcizumab, the collaboration includes up to five preclinical- or discovery-stage biologics programs: OncoMed’s anti-DLL4/VEGF bispecific antibody and up to four additional biologics programs targeting either the RSPO-LGR CSC pathway or an additional undisclosed CSC pathway. Celgene obtains exclusive options on these programs during or after completion of certain Phase I clinical trials to be conducted by OncoMed. For the anti-DLL4/VEGF bispecific antibody and three of the four additional biologics programs, OncoMed retains 50/50 U.S. profit sharing and co-commercialization terms, plus 1/3 OncoMed and 2/3 Celgene global development cost-sharing and mid-single digit to mid-double digit royalties outside the profit-sharing territory. On the fourth biologics program, Celgene would receive an exclusive worldwide license, with OncoMed receiving high-single digit to mid-double digit royalties on worldwide sales. Celgene also obtains an option to conduct small molecule research, development, and commercialization in an undisclosed CSC pathway, with OncoMed eligible to receive milestones and low- to mid-single digit royalties on any resulting small molecule anti-cancer product candidates.

Under the terms of the agreement, OncoMed will receive an upfront payment of $155 million, and Celgene will also purchase approximately $22.25 million in a private placement of newly issued shares of OncoMed’s common stock at a price of $15.13 per share.

The collaboration also includes option exercise payments and payments for achievement of development, regulatory and commercial milestones, paid on a per-program basis. For demcizumab, these payments could total up to approximately $790 million, and include an undisclosed payment for achievement of pre-determined safety criteria in Phase II clinical trials. For the anti-DLL4/VEGF bispecific antibody, option exercise, development, regulatory and commercial payments could total up to $505 million. For the other four biologics, each program is eligible for approximately $440 million of option exercise, development, regulatory and commercial payments. OncoMed could also receive more than $100 million in option exercise, development and regulatory approval payments for the small molecule program. Such total payments include milestones for regulatory approvals in multiple indications per program. OncoMed retains worldwide rights to certain targets in multiple pathways that do not become collaboration programs with Celgene.

“Through this major alliance with Celgene, we gain substantial resources that will enable us to continue to discover and develop new therapeutics independently while positioning OncoMed for substantial potential downstream value and profits. Importantly, by retaining co-development and co-commercialization rights to up to five biologic product candidates in our pipeline, we expect to add commercial capabilities to our core research and development competencies as we continue to build a premier oncology biotherapeutics company,” said Paul J. Hastings, OncoMed’s Chairman and CEO. “Celgene is a preeminent biopharmaceutical innovator with a successful track record of translating unique science into disease-altering therapies that benefit patients, healthcare and society. We can greatly benefit from their expertise and look forward to many years of successful collaboration.”

Tom Daniel, President, Global Research & Early Development, of Celgene said, “We are very pleased to enter into this broad based collaboration with OncoMed, one that holds great promise for cancer patients.  Demcizumab’s substantial early clinical activity warrants aggressive yet careful evaluation in several indications where we have strength, including non-small cell lung cancer and pancreatic cancer. The earlier partnerships in the RSPO-LGR and another, undisclosed cancer stem cell pathway provide us complementary and strategically valuable targeting opportunities across both biologic and small molecule modalities in the cancer stem cell arena where OncoMed has provided leadership and great strength.”

Latham & Watkins LLP and Leerink Swann LLC acted as advisors to OncoMed for this transaction.

OncoMed Conference Call

OncoMed management will host a conference call today beginning at 8:30 a.m. ET/5:30 a.m. PT to discuss today’s announcement regarding this strategic collaboration with Celgene Corporation.

Analysts and investors can participate in the conference call by dialing (855) 420-0692 for domestic callers and (484) 756-4194 for international callers. The live conference call will also be webcast and available on the Investor Relations page of OncoMed’s website at www.oncomed.com. Please access the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. A telephone replay will be available following the conclusion of the call by dialing (855) 859-2056 for domestic callers and (404) 537-3406 for international callers using the passcode 19812706.

About Cancer Stem Cells

Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. OncoMed has advanced five distinct anti-CSC targeting product candidates into clinical trials, including demcizumab (OMP-21M18). OncoMed believes its product candidates are distinct from the current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer.

About Demcizumab (OMP-21M18)

Demcizumab is a humanized monoclonal antibody that inhibits Delta-Like Ligand 4 (DLL4) in the Notch signaling pathway.  Two Phase Ib combination trials of demcizumab are ongoing: demcizumab with standard-of-care in first-line advanced pancreatic cancer patients, and demcizumab with standard-of-care carboplatin and pemetrexed (Alimta™) in first-line advanced non-small cell lung cancer (NSCLC) patients. In addition, a Phase Ib/II trial of demcizumab and paclitaxel in patients with platinum-resistant ovarian cancer is ongoing at MD Anderson Cancer Center. Demcizumab is part of OncoMed’s collaboration with Celgene Corporation.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells.  OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (Anti-DLL4, OMP-21M18), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1), vantictumab (Anti-Fzd7, OMP-18R5), and OMP-54F28 (Fzd8-Fc), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development, Anti-DLL4/Anti-VEGF bispecific and Anti-RSPO3, with Investigational New Drug filings planned for as early as 2014. OncoMed is also pursuing discovery of additional novel anti-CSC product candidates.  OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company’s website: www.oncomed.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding OncoMed Pharmaceuticals, Inc., they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including OncoMed’s expectations regarding the ability of OncoMed to advance its research and development pipeline, including its discovery and preclinical pipeline and its anti-CSC therapeutics in clinical trials; OncoMed’s expectations regarding its ability to co-develop and co-commercialize demcizumab or any other product candidate; the receipt of the upfront payment from Celgene and the completion of the private placement of shares of OncoMed’s common stock; OncoMed’s ability to discover and develop novel anti-CSC therapeutics; OncoMed’s expectations regarding its ability to realize substantial potential downstream value and profits from its alliance with Celgene; and the potential of OncoMed’s product candidates to significantly impact cancer treatment and the clinical outcome of patients with cancer. Such forward-looking statements involve substantial risks and uncertainties that could cause OncoMed’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; OncoMed’s dependence on its collaboration partners, including Celgene, Bayer and GSK, for the funding of its partnered programs; OncoMed’s dependence on the development and marketing efforts of its partners for the commercial success of its partnered product candidates; OncoMed’s reliance on third parties to conduct certain preclinical studies and all of its clinical trials; OncoMed’s reliance on single source third-party contract manufacturing organizations to manufacture and supply its product candidates; OncoMed’s ability to validate, develop and obtain regulatory approval for companion diagnostics; OncoMed’s ability to achieve market acceptance and commercial success of its product candidates once regulatory approval is achieved; OncoMed’s ability to discover, develop and commercialize additional product candidates; the ability of competitors to discover, develop or commercialize competing products more quickly or more successfully; OncoMed’s dependence on its Chairman and Chief Executive Officer, its Chief Scientific Officer, its Chief Medical Officer and other key executives; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate OncoMed’s patents or proprietary rights; and the ability of OncoMed’s proprietary rights to protect its technologies and product candidates. OncoMed undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to OncoMed’s business in general, see OncoMed’s Prospectus filed with the Securities and Exchange Commission on July 18, 2013 and OncoMed’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2013, filed with the Securities and Exchange Commission on November 13, 2013.

CONTACT: OncoMed Pharmaceuticals
         Investors
         Shari Annes
         (650) 888-0902
         shari.annes@oncomed.com

         Media
         BCC Partners
         Karen L. Bergman or
         Michelle Corral
         (650) 575-1509 or (415) 794-8662
         kbergman@bccpartners.com or mcorral@bccpartners.com

         Celgene Corporation
         Investors:
         (908) 673-9628
         investors@celgene.com

         Media:
         (908) 673-2275
         media@celgene.com

(JMSN) to Present at LD Micro Conference in Los Angeles, December 4

Live Company Presentation to Be Delivered by CEO Michael Stanford

(HOTR) Appalachian Mountain Brewery to Acquire North Carolina Natural Energy

CHARLOTTE, N.C., Dec. 3, 2013 — In a strategic move to prepare for wholesale distribution of its award winning craft beer, Boone, NC-based Appalachian Mountain Brewery announced today it entered into a letter of intent to acquire North Carolina Natural Energy, Inc., a publicly traded company, (OTC:NCNE). North Carolina Natural Energy, Inc., a Florida Corporation headquartered in the foothills of NC will change its name to Appalachian Mountain Brewery Inc. and begin trading as a craft brewery. Terms have been agreed upon and approved by both parties with closing expected before year end.

North Carolina Natural Energy, Inc. provides a wholesale liquor, beer and wine license with US Alcohol and Tobacco Tax and Trade Bureau (TTB.gov) as well as access to the public markets including a sophisticated shareholder group. Notably, one of NCNE’s shareholders, Chanticleer Holdings, Inc. (Nasdaq:HOTR) and its CEO Mike Pruitt, played a key advisory role in facilitating this combination. “Sean and his team have created international award-winning craft beers that are gaining brand recognition throughout our region. We look forward to showcasing AMB’s craft beers in our restaurants and assisting in its regional distribution. Our Company will continue to assist AMB in its growth and expansion to becoming a global brand,” Mike Pruitt commented.

Sean Spiegelman, founder of Appalachian Mountain Brewery will be appointed CEO of the publicly traded company and continue to manage the brewery by offering a unique experience through community stewardship and environmental sustainability as a core part of the business. The brewery’s modern equipment utilizes American Made JV Northwest Brewing equipment, a 5KW array of solar panels to offset electricity along with a recapturing system to save water in the brew process. In keeping with the brewery’s sustainable mission to reduce, reuse and recycle, AMB has a grain exchange program whereby all spent grain is donated to local farms. AMB also has a “Pints For Non-Profits Program,” whereby a portion of proceeds from each beer sold is donated to local non-profit organizations.

Craft brewer retail dollar volume in 2012 was estimated at $10.2 billion, up from $8.7 billion in 2011. Appalachian Mountain Brewery is at the forefront of a growing trend where craft brewing has increased by 15% and overall beer sales topped $99 billion in 2012.

About Appalachian Mountain Brewery, LLC

Appalachian Mountain Brewery, the Official Brewery of the Appalachian Mountains, not only makes seriously delicious craft beer, but focuses its business model on sustainability, community, and philanthropy. AMB won two Gold Medals and won the overall categories in the 2013 United States Open Beer Championship for its Honey Badger Blonde Ale and California Common. AMB competed against the biggest and best breweries from around the world where over 2,500 beers competed in 68 categories for aroma, appearance, mouth feel, flavor and overall impression. Appalachian Mountain Brewery, located at 3,333 feet elevation atop the Appalachian Mountain Range in Boone, NC, is certified by the NC GreenTravel Initiative, a program that recognizes state travel-related businesses that employ healthy environmental practices. AMB is within minutes of world-class destinations such as Grandfather Mountain, Tweetsie Railroad, Beech Mountain, Sugar Mountain, Appalachian Ski Resorts and the three-time National Football Champions Appalachian State University.

For further information, please visit: www.appalachianmountainbrewery.com
Facebook: https://www.facebook.com/appalachianmountain.brewery
Awards: www.usopenbeer.com
Sustainability: http://portal.ncdenr.org/web/deao/ncgreentravel-attractionlist

About Chanticleer Holdings, Inc.

Chanticleer Holdings (Nasdaq:HOTR) is focused on expanding the Hooters® casual dining restaurant brand in international emerging markets and American Roadside Burgers Inc (“ARB”), a Charlotte, N.C. based chain. Chanticleer currently owns in whole or part of the exclusive franchise rights to develop and operate Hooters restaurants in South Africa, Hungary and parts of Brazil, and has joint ventured with the current Hooters franchisee in Australia, while evaluating several additional international opportunities. The Company currently owns and operates in whole or part of seven Hooters restaurants in its international franchise territories: Durban, Johannesburg, Cape Town and Emperor’s Palace in South Africa; Campbelltown in Australia; Budapest in Hungary; and Nottingham in the United Kingdom. ARB, purchased by Chanticleer Holdings on October 1, 2013, has a total of 5 casual restaurants — 1 location in Smithtown, N.Y., 2 locations in Charlotte, N.C., 1 location in Columbia, S.C., and the newest location is in Greenville, S.C. The Company also owns a majority interest in JF Restaurants, LLC and JF Franchising Systems, fresh food-focused casual dining established with 5 restaurant locations.

For further information, please visit www.chanticleerholdings.com
Facebook: www.Facebook.com/ChanticleerHOTR
Twitter: http://Twitter.com/ChanticleerHOTR

For further information on Hooters of America, visit www.Hooters.com
Facebook: www.Facebook.com/Hooters
Twitter: http://Twitter.com/Hooters

Safe Harbor

This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipate,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. We undertake no obligation to update such statements to reflect subsequent events.

CONTACT: Clinton Walker
         (704) 965-7520

(CXM) LifeAgain’s Bluemetric Select Life Insurance Now Offered At Lifequotes.com

First National Direct Life Insurance Marketing Company to Offer LifeAgain’s BlueMetric Select Life Insurance Program for Men with Active Localized Prostate Cancer

SAN DIEGO, Dec. 3, 2013 — LifeAgain Insurance Solutions Inc., a wholly-owned subsidiary of Cardium Therapeutics (NYSE MKT: CXM), today announced that its BlueMetric Select term life insurance program is now available through Life Quotes, Inc., the first national direct marketing company to offer LifeAgain’s term life insurance program for men with active localized prostate cancer.  Life Quotes owns and operates Lifequotes.com, an award-winning life insurance exchange staffed by approximately 100 insurance professionals.

“We are pleased to offer LifeAgain’s BlueMetric Select term life insurance program on the LifeQuotes.com platform,” stated Christopher J. Reinhard, CEO of LifeAgain.  “LifeAgain has effectively extended life insurance eligibility to as many as 400,000 men annually following their cancer diagnosis or upon the completion of prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.  The purchase of life insurance online is  steadily rising as more and more customers turn to the internet to purchase insurance.  We look forward to working with Life Quotes, and to introducing our term life insurance program for men with prostate cancer to other direct marketers to allow additional online accessibility to our BlueMetric Select term life insurance program.”

“The LifeAgain BlueMetric term life insurance plan represents a unique and significant breakthrough for certain newly-diagnosed prostate cancer patients,” remarked Robert Bland, CEO of LifeQuotes, Inc.  “We’re delighted to offer this groundbreaking new life insurance plan on our platform for the benefit of our customers who may have prostate cancer.  The competitively-priced LifeAgain BlueMetric life insurance plan represents a major marketplace advancement in terms of combining the latest bio-medical knowledge with actuarial science for the benefit of prostate cancer patients.”

The Life Insurance Direct Marketing Association (LIDMA) recently reported that, “direct response selling of life insurance is the fastest growing segment of the life insurance industry today.  Each year a higher percentage of overall life insurance sales can be attributed to some type of direct marketing effort.  More than $300 million in life insurance premium is initiated each year from direct response efforts, and direct sales of life insurance represents as much as 10% of all policy sales on an annual basis.”

For cancer patients who often feel a genuine need for life insurance, it is typically unavailable. Life insurance generally only becomes an option after five years of being cancer free.  Even then, it can be an uphill battle depending on the type, stage, grade of the cancer, and the treatment plan.  LifeAgain’s BlueMetric Select program was specifically designed to provide eligible men with term life insurance coverage following a cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.  Importantly, coverage is also now available to prostate cancer patients who are in a “watchful waiting” treatment plan, including younger men who traditionally have been denied life insurance with few exceptions.

About BlueMetric Select Term Life Insurance

The BlueMetric Select program is been designed for men aged 45-65, who are in otherwise good health and who have low- to medium-risk active localized prostate cancer, which has been confirmed by a recent biopsy, and for men who have recently completed prostate cancer surgery. This program seeks to provide term life insurance coverage and may include an automatic renewal option (following the initial ten-year term), the right to convert into universal life insurance, and an accelerated benefit in the event of a terminal illness. The BlueMetric Select Program is designed to offer substantial coverage levels, ranging from $100,000 to $1,000,000, without waiting periods, so an individual can begin the application process on the day of his prostate cancer diagnosis, or immediately following completion of prostate cancer surgery.  Additional information about the BlueMetric Select Program is available at www.lifeagain.com/wp-content/pdfs/symetra-level-term-fact-sheet.pdf.

About Life Quotes, Inc.

Privately-held Life Quotes, Inc., headquartered in Darien, IL, operates an Internet-based life insurance price comparison service and brokerage operation for consumers in all 50 states.  Over 300,000 people have purchased policies from Life Quotes since the firm’s founding in 1984.  The company provides instant life insurance quotes and companion expert advice through 100 insurance professionals. Visitors to www.Lifequotes.com can instantly and anonymously compare the rates of 30 leading life insurance companies in seconds and have the freedom to apply to any company shown.

About LifeAgain

LifeAgain Insurance Solutions is an advanced medical data analytics business and national life insurance agency that is focused on the development, marketing and sale of “survivable risk” term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards.  LifeAgain recently launched its initial BlueMetric Select term life insurance program, underwritten by Symetra Life Insurance, for men with active localized prostate cancer.  LifeAgain plans to develop additional new and innovative life insurance solutions for men and women with other medical conditions. For more information about LifeAgain, visit www.lifeagain.com.

About Cardium

Cardium is a health sciences and biotechnology regenerative medicine company. Cardium has three business units: (1) Angionetic Therapeutics™, focused on the late-stage clinical development of Generx^®, an angiogenic gene therapy product candidate for the treatment for cardiac microvascular insufficiency due to advancing coronary artery disease; (2) Activation Therapeutics™, a regenerative medicine wound healing technology and commercialization platform, that includes Excellagen^®, an FDA-cleared advanced wound care product; and (3) LifeAgain® Insurance Solutions, an advanced medical data analytics platform that supports the Company’s BlueMetric Select term life insurance program underwritten by Symetra Life Insurance for men with active localized prostate cancer.  For more information about Cardium visit www.cardiumthx.com.

Forward-Looking Statements

This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes.  Such statements are necessarily based on estimates and assumptions that are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and subject to change. Moreover, we operate in a rapidly changing and competitive environment. These uncertainties and contingencies could cause actual results to differ materially from those expressed, and therefore undue reliance should not be placed upon such statements.  The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.

LifeAgain Insurance Solutions Inc. is a life insurance agency incorporated in Delaware and registered in New York as LifeAgain Insurance Services. Insurance issued under the BlueMetric Select program may not be available in all states.

For the education of Producers and Brokers Only – not for public use. 

Copyright 2013 LifeAgain Insurance Solutions Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.lifeagain.com.

LifeAgain^®, BlueMetric Select™, Decision Rule Adaption™, and ADAPT™ are trademarks of

LifeAgain Insurance Solutions Inc. or Cardium Therapeutics, Inc.

Other trademarks belong to their respective owners.

(CLPI) Majority Ownership of Money-on-Mobile Approved

Calpian, Inc. (OTCQB:CLPI) announced today that the Finance Ministry of the Government of India through the Foreign Investment Promotion Board (FIPB) has unconditionally approved Calpian’s application to own up to 74% of My Mobile Payments, Ltd. which currently operates as Money-on-Mobile (MOM) in India.

“The FIPB approval allows Calpian, Inc. to own a majority of Money-on-Mobile and eventually consolidate our financials, resulting in a clear picture to the market of Money-on-Mobile’s growth in India. We are excited about what the future holds for Calpian, as we are only just beginning to penetrate the broader market in India. The Money-on-Mobile team has executed their business plan brilliantly which has resulted in over 300% growth in the 20 months since we made our first investment there,” said Calpian, Inc. CEO Harold Montgomery.

“We are encouraged that the FIPB has approved this expansion of the Calpian/MOM partnership which has been so very successful to date. We look forward to the continuation of our growth through this investment partnership,” added Money-on-Mobile Managing Director, Shashank Joshi.

About Calpian, Inc. and Money-on-Mobile

Calpian, Inc. (OTCQB: CLPI) is a publicly traded company with corporate offices in Dallas, Texas and mobile payments emerging-market operations through its subsidiary in India. Calpian’s Indian subsidiary offers Money-on-Mobile, a pre-paid mobile payment solution, to more than 167,000 Indian retail locations with over 75 million unique users. Calpian’s management team has over 70 years in combined experience in the payments business. Calpian’s CEO, Harold Montgomery, is a recognized industry leader who has provided expert testimony to the U.S. Congress and Federal Reserve Bank on payments-related issues and regularly appears in numerous industry publications, such as Transaction World Magazine. Please visit our website at www.calpian.com for more information.

(MKTO) Announces Partnership with Marketing Software Expert, Marketo

EAST NORRITON, Pa., Dec. 2, 2013 — HighPoint Solutions, LLC, a premier, global provider of specialized IT services dedicated to the Life Sciences and Healthcare industries, announced today a new strategic partnership with Marketo (NASDAQ: MKTO), the leading cloud-based marketing software platform for building and sustaining engaging customer relationships. Marketo understands the marketing and sales world is rapidly changing, including the increasing number of marketing channels to manage from search marketing to e-commerce, social media, and mobile. Marketo validates it is more important than ever for companies to effectively use these channels to establish strong long-lasting relationships with their customers, achieve acquisition success, and promote sustained customer lifetime value.

Sam Schmitt, Vice President of Commercial Excellence at HighPoint Solutions, said, “Our Life Sciences clients are requesting solutions to improve multi-channel marketing capabilities for their complex customer environment including payers, health care professionals, and patients.” Schmitt continued, “Marketo’s best in class marketing automation software, combined with HighPoint’s industry expertise, enables us to bring Life Sciences manufacturers customized marketing automation solutions that can create competitive advantage for our joint customers.  We are truly excited about the value our partnership will bring to each other and most importantly our joint customers.”

“By combining HighPoint’s deep expertise in Life Sciences and Healthcare with the power of Marketo’s marketing platform, we can deliver even more value for our mutual clients,” said Mark Sheridan, Vice President of Business Development at Marketo. “As the Healthcare and Life Sciences industries are evolving, the ability to engage consumers, patients and providers across multiple channels and measuring the ROI is becoming even more critical.”

HighPoint focuses on the needs of their clients by continually improving their consultants with the knowledge and resources of current trends, strategies, and technologies available to deliver a comprehensive strategic package.

About HighPoint Solutions
HighPoint Solutions is a premier, global provider of specialized IT with vertically-focused business consulting, system integration, professional service, and managed hosting solutions for life sciences and healthcare companies.  Since 2000, our 500+ consultants have provided business consulting and technology solutions that continue to deliver business value and competitive advantage to more than 140 clients globally.

For more information about HighPoint Solutions and their upcoming events, please visit http://highpointsolutions.com/

About Marketo: Marketing Software. Easy, Powerful, Complete.
Marketo (NASDAQ: MKTO) provides the leading cloud-based marketing software platform for companies of all sizes to build and sustain engaging customer relationships.  Spanning today’s digital, social, mobile and offline channels, the Marketo^® solution includes a complete suite of applications that help organizations acquire new customers more efficiently, maximize customer loyalty and lifetime value, improve sales effectiveness, and provide analytical insight into marketing’s contribution to revenue growth. Marketo’s applications are known for their breakthrough ease-of-use, and are complemented by the Marketing Nation™, a thriving network of more than 150 LaunchPoint™ ecosystem partners and over 30,000 marketers who share and learn from each other to grow their collective marketing expertise.  The result for modern marketers is unprecedented agility and superior results.

Headquartered in San Mateo, CA with offices in Europe and Australia, Marketo serves as a strategic marketing partner to more than 2,500 large enterprises and fast-growing small companies across a wide variety of industries. For more information, visit www.marketo.com.

Marketo, the Marketo logo, Marketing Nation and LaunchPoint are trademarks of Marketo, Inc. All other trademarks are the property of their respective owners.

(EDS) Enters into a Merger Agreement for a “Going Private” Transaction

FUJIAN, China, Dec. 2, 2013 — Exceed Company Ltd. (NASDAQ: EDS) (“Exceed” or the “Company”), one of the leading domestic sportswear brands in China, today announced that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with Pan Long Company Limited (“Parent”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and wholly owned by Mr. Shuipan Lin (“Mr. Lin”), the Company’s Chairman and Chief Executive Officer, and Pan Long Investment Holdings Limited (“Merger Sub”), a business company with limited liability incorporated under the laws of the British Virgin Islands (“BVI”) and a wholly owned subsidiary of Parent, pursuant to which Parent will acquire the Company for US$1.78 per ordinary share of the Company (a “Share”).  This represents a 19.5% premium over the closing price of US$1.49 on August 16, 2013, the last trading day prior to the Company’s announcement on August 19, 2013 that it had received a “going private” proposal, and a 24.4% premium over the volume-weighted average closing price of the Company’s Shares during the 30 trading days prior to August 16, 2013.  The consideration to be paid to holders of Shares implies an equity value for the Company of approximately US$60.1 million, on a fully diluted basis.

Upon consummation of the transactions contemplated under the Merger Agreement, Parent will be beneficially owned by Mr. Lin, (and/or entities affiliated with or related to them) (collectively, the “Buyer Group”), together with seven existing shareholders of the Company (and/or entities affiliated with or related to them) who have elected to transfer, prior to the closing, their Shares to Parent in exchange for newly issued shares of Parent (the “Rollover Shareholders”).

Subject to the terms and conditions of the Merger Agreement, at the effective time of the merger (the “Effective Time”), Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the “Merger”).  At the Effective Time, each of the Company’s Shares issued and outstanding immediately prior to the Effective Time will be cancelled in exchange for the right to receive US$1.78 in cash and without interest, except for the excluded Shares (the “Excluded Shares”), which include: (i) Shares legally owned by Parent; and (ii) dissenting Shares (the “Dissenting Shares”) owned by holders of Shares who have validly exercised and not effectively withdrawn or lost their dissenter’s rights pursuant to Section 179 of the BVI Business Companies Act, 2004, as amended (the “BVI Companies Act”) (the “Dissenting Shareholders”). Each Excluded Share issued and outstanding immediately prior to the Effective Time will be cancelled and will cease to exist, and no consideration will be delivered with respect thereto. Each Dissenting Share will be cancelled at the Effective Time for the right to receive the fair value of such Shares as determined in accordance with the provisions of the BVI Companies Act.

Parent has received from Mr. Lin an equity commitment letter, pursuant to which Mr. Lin has committed to subscribe for ordinary shares in Parent in the amount of US$19,545,858 subject to adjustment in certain cases.  Mr. Lin has also entered into a limited guarantee in favor of the Company.

The Company’s board of directors, acting upon the unanimous recommendation of the independent committee formed by the board of directors (the “Independent Committee”), approved the Merger Agreement and the Merger and resolved to recommend that the Company’s shareholders vote to authorize and approve the Merger Agreement and the Merger. The Independent Committee, which is comprised solely of independent and disinterested directors of the Company who are unaffiliated with any of Parent, Merger Sub, or the Buyer Group, negotiated the terms of the Merger Agreement with the assistance of its financial and legal advisors.

The Merger, which is currently expected to close in the first quarter of 2014, is subject to customary closing conditions, including the approval by an affirmative vote of shareholders representing more than seventy percent (70%) of the outstanding Shares of the Company as of the record date, present and voting in person or by proxy as a single class at an extraordinary general meeting of the Company’s shareholders which will be convened to consider the approval of the Merger Agreement and the Merger. As of the date of the Merger Agreement, the Rollover Shareholders have agreed under a voting agreement to vote all in favor of the Merger Agreement and consummation of the transactions contemplated thereby, including the Merger. If completed, the Merger will result in the Company becoming a privately held company and its Shares will no longer be listed on Nasdaq.

Houlihan Lokey (China) Limited is serving as financial advisor to the Independent Committee. K&L Gates LLP is serving as United States legal advisor to the Independent Committee and the Company. Walkers is serving as BVI legal advisor to the Independent Committee.  Skadden, Arps, Slate, Meagher & Flom LLP is serving as United States legal advisor to the Buyer Group.

Additional Information about the Transaction:

In connection with the execution of the Merger Agreement, will furnish to the Securities and Exchange Commission (the “SEC”) a report on Form 6-K regarding the proposed transactions described in this announcement, which will include as an exhibit to such filing the Merger Agreement. Any person desiring details regarding the proposed Merger are urged to review these documents, which will be available at the SEC’s website (http://www.sec.gov).

In connection with the proposed Merger, the Company will prepare and mail a proxy statement to its shareholders. In addition, certain participants in the proposed Merger will prepare and mail to the Company’s shareholders a Schedule 13E-3 transaction statement. These documents will be filed with or furnished to the SEC. INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS. In addition to receiving the proxy statement and Schedule 13E-3 transaction statement by mail, shareholders also will be able to obtain these documents, as well as other filings containing information about the Company, the proposed Merger and related matters, without charge, from the SEC’s website (http://www.sec.gov) or at the SEC’s public reference room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. In addition, these documents can be obtained, without charge, by contacting the Company at the following address and/or telephone number:

Exceed Company Ltd.
Level 12, China Minmetals Tower,
79 Chatham Road South,
Tsim Sha Tsui, Hong Kong.
Phone: +852 3975-8116

The Company and certain of its directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from shareholders with respect to the Merger. Information regarding the persons or entities who may be considered “participants” in the solicitation of proxies will be set forth in the proxy statement and Schedule 13E-3 transaction statement relating to the Merger when it is filed with the SEC. Information regarding certain of these persons and their beneficial ownership of the Company’s Shares as of December 31, 2012 is also set forth in the Company’s Form 20-F, which was filed with the SEC on March 27, 2013 and amended on September 12, 2013. Additional information regarding the interests of such potential participants will be included in the proxy statement and Schedule 13E-3 transaction statement and the other relevant documents filed with the SEC when they become available.

This announcement is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that may be made with the SEC should the proposed Merger proceed.

About Exceed Company Ltd.

Exceed Company Ltd. designs, develops and engages in wholesale of footwear, apparel and accessories under its own brand, XIDELONG, in China. Since it began operations in 2002, Exceed has targeted its growth on the consumer markets in second and third-tier cities in China. Exceed has three principal categories of products: (i) footwear, which comprises running, leisure, basketball, skateboarding and canvas footwear, (ii) apparel, which mainly comprises sports tops, pants, jackets, track suits and coats, and (iii) accessories, which mainly comprise bags, socks, hats and caps. Exceed Company Ltd. currently trades on Nasdaq under the symbol “EDS”.

Forward-Looking Statements:

This announcement contains forward-looking statements that are based on our current expectations, assumptions, estimates and projections about us and our industry. All statements other than statements of historical fact in this form are forward-looking statements. These forward-looking statements can be identified by words or phrases such as “may”, “will”, “expect”, “anticipate”, “estimate”, “plan”, “believe”, “is/are likely to” or other similar expressions. These forward-looking statements involve various risks and uncertainties. The forward-looking statements made in this announcement relate only to events, including the Merger Agreement and its related agreements described above or information as of the date on which this announcement is published. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date this announcement is published or to reflect the occurrence of unanticipated events.

For further information, please contact:

Investor Relations
Exceed Company Ltd.
Vivien Tai
+852 3975-8116
ir@xdlong.cn

(DGLY) Receives Initial DVM-250 Order From Kansas City Transportation Group

Company Targets 5,000+ Vehicles Operated by Affiliates of Veolia Transportation

(GOGO) Receives Supplemental Type Certificate for Ku-Satellite

STC Clears Way for Launch of International Wi-Fi Service

ITASCA, Ill., Dec. 2, 2013 — Gogo (NASDAQ: GOGO), the world leader of in-flight connectivity and a pioneer in wireless in-flight digital entertainment solutions, passed a key milestone in launching its international connectivity service by receiving an STC to install its Ku-satellite technology on Boeing 747-400 aircraft.

(Logo: http://photos.prnewswire.com/prnh/20110715/CG34837LOGO)

Gogo will begin testing the new service immediately and plans to offer the service for customer usage by the first quarter of 2014.  The technology will give travelers and crew access to the Internet.  The service will also offer passengers Gogo Vision, Gogo’s wireless in-flight entertainment service.

“This is a major milestone for Gogo as a company as it is a big step in clearing the way for international service,” said Michael Small, Gogo’s president and CEO. “We are proud to offer a consistent global connectivity experience anywhere our customers fly; whether it’s on regional aircraft, domestic mainline aircraft or these Ku-equipped 747s that travel around the world.”

Gogo plans to continue installing equipment on 747-400 aircraft throughout 2014, in addition to other international aircraft.

About Gogo
Gogo is the global leader of in-flight connectivity and wireless in-flight digital entertainment solutions. Using Gogo’s exclusive products and services, passengers with Wi-Fi enabled devices can get online on more than 2,000 Gogo equipped commercial aircraft. In-flight connectivity partners include American Airlines, Air Canada, AirTran Airways, Alaska Airlines, Delta Air Lines, Japan Airlines, United Airlines, US Airways and Virgin America. In-flight entertainment partners include American Airlines, Delta Air Lines, Scoot and US Airways. In addition to its commercial airline business, Gogo has more than 6,500 business aircraft outfitted with its communications services.

Back on the ground, Gogo’s 600+ employees in Itasca, IL, Broomfield, CO and London are working to continually redefine flying as a productive, socially connected, and all-around more satisfying experience. Connect with Gogo at www.gogoair.com, on Facebook at www.facebook.com/gogo and on Twitter at www.twitter.com/gogo.

(FREE) Announces Reverse Split of Common Stock

Athens, Greece, Dec. 2, 2013 — December 2, 2013 — FreeSeas Inc. (Nasdaq: FREE) (“FreeSeas” or the “Company”), a transporter of dry-bulk cargoes through the ownership and operation of a fleet of Handysize and Handymax vessels, announced today that the Company’s Amended and Restated Articles of Incorporation were amended to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio of one new share for every 5 shares currently outstanding.

The Company anticipates that its common stock will begin trading on a split adjusted basis when the market opens on December 2, 2013. FreeSeas’ common stock will continue to trade under the symbol “FREE.” The common shares will also trade under a new CUSIP number Y26496300.

The reverse stock split will consolidate 5 shares of common stock into one share of common stock at a par value of $.001 per share. The reverse stock split will not affect any shareholder’s ownership percentage of FreeSeas’ common shares, except to the limited extent that the reverse stock split would result in any shareholder owning a fractional share. Fractional shares of common stock will be rounded up to the nearest whole share.

After the reverse stock split takes effect, shareholders holding physical share certificates will receive instructions from American Stock Transfer and Trust Company LLC, the Company’s exchange agent, regarding the process for exchanging their shares.

About FreeSeas Inc.

FreeSeas Inc. is a Marshall Islands corporation with principal offices in Athens, Greece. FreeSeas is engaged in the transportation of drybulk cargoes through the ownership and operation of drybulk carriers. Currently, it has a fleet of Handysize and Handymax vessels. FreeSeas’ common stock trades on the Nasdaq Capital Market under the symbol FREE. Risks and uncertainties are described in reports filed by FreeSeas Inc. with the SEC, which can be obtained free of charge on the SEC’s website at http://www.sec.gov. For more information about FreeSeas Inc., please visit the corporate website, www.freeseas.gr.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth strategy and measures to implement such strategy. Words such as ”expects,” ”intends,” ”plans,” ”believes,” ”anticipates,” ”hopes,” ”estimates,” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to be correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, changes in the demand for dry bulk vessels; competitive factors in the market in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact Information:

At the Company

FreeSeas Inc.

Dimitris Papadopoulos, Chief Financial Officer

011-30-210-45-28-770

Fax: 011-30-210-429-10-10

dp@freeseas.gr

www.freeseas.gr

(HOTR) Announces Investment in Beacher’s Madhouse in Las Vegas, Nevada

(OREX) to Present at the 25th Annual Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 27, 2013  — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 25th Annual Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Tuesday, December 3^rd  at 11:00 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company’s Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave, which the Company is evaluating in the Light Study, a cardiovascular outcomes trial being conducted under a Special Protocol Assessment (SPA) with the FDA. Based on successful results of the Light Study, the Company plans to resubmit the Contrave NDA to the FDA with potential approval by June 2014.The Company’s other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

(INBK) Closing of Upsized Public Offering, Exercise of Over-Allotment Option

First Internet Bancorp (NASDAQ: INBK), the parent company of First Internet Bank of Indiana (the “Bank”), today announced the closing of its underwritten public offering of 1,587,000 shares of its common stock, including 207,000 shares issued pursuant to the underwriters’ 30-day option, at a price to the public of $20.00 per share. The net proceeds of the Company after deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $29.1 million.

Sandler O’Neill + Partners, L.P. served as sole book-running manager of the offering, and Keefe, Bruyette & Woods, Inc. acted as co-manager. Faegre Baker Daniels LLP served as legal counsel to the Company. Patton Boggs LLP served as legal counsel to the underwriters.

A registration statement relating to these securities has been filed with, and declared effective by the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale of securities would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

The offering was made only by means of a prospectus, copies of which may be obtained from Sandler O’Neill + Partners, L.P., 1251 Avenue of the Americas, 6^th Floor, New York, NY 10020, (866) 805-4128. The registration statement may also be accessed through the SEC’s website.

First Internet Bancorp

First Internet Bancorp (NASDAQ: INBK) is the parent company of First Internet Bank of Indiana (www.firstib.com), a premier provider of online retail and business banking services nationwide. First Internet Bank opened for business in 1999. The Bancorp became the parent of the Bank effective March 21, 2006.

About First Internet Bank of Indiana

First Internet Bank of Indiana is the first state-chartered, FDIC-insured institution to operate solely via the Internet and has customers in all 50 states. Deposit services include checking accounts, regular and money market savings accounts, CDs and IRAs. First Internet Bank also offers consumer loans, conforming mortgages, jumbo mortgages, home equity loans and lines of credit, and commercial loans. This year, First Internet Bank was named one of the Best Places to Work in Indiana by the Indiana Chamber of Commerce, one of the Best Banks to Work For by American Banker Magazine, and the top Online Originator by Mortgage Technology. The Bank is a wholly owned subsidiary of First Internet Bancorp.

(PEIX) to Present at the LD Micro Conference on December 3, 2013

SACRAMENTO, Calif., Nov. 27, 2013  — Pacific Ethanol, Inc. (Nasdaq:PEIX), the leading marketer and producer of low-carbon renewable fuels in the Western United States, announced management will present at the LD Micro Conference at the Luxe Sunset Bel Air Hotel in Los Angeles on Tuesday, December 3, 2013 at 11:30 a.m. Pacific Time.

A live audio webcast of the company’s presentation will be available on the investor relations section of the company’s website at www.pacificethanol.net starting at approximately 11:30 a.m. Pacific Time/2:30 p.m. Eastern Time on Tuesday, December 3, 2013.

About Pacific Ethanol, Inc.

Pacific Ethanol, Inc. (Nasdaq:PEIX) is the leading marketer and producer of low-carbon renewable fuels in the Western United States. Pacific Ethanol also sells co-products, including wet distillers grain (“WDG”), a nutritious animal feed. Serving integrated oil companies and gasoline marketers who blend ethanol into gasoline, Pacific Ethanol provides transportation, storage and delivery of ethanol through third-party service providers in the Western United States, primarily in California, Arizona, Nevada, Utah, Oregon, Colorado, Idaho and Washington. Pacific Ethanol has an 85% ownership interest in New PE Holdco LLC, the owner of four ethanol production facilities. Pacific Ethanol operates and manages the four ethanol production facilities, which have a combined annual production capacity of 200 million gallons. The facilities in operation are located in Boardman, Oregon, Burley, Idaho and Stockton, California, and one idled facility is located in Madera, California. The facilities are near their respective fuel and feed customers, offering significant timing, transportation cost and logistical advantages. Pacific Ethanol’s subsidiary, Kinergy Marketing LLC, markets ethanol from Pacific Ethanol’s managed plants and from other third-party production facilities, and another subsidiary, Pacific Ag. Products, LLC, markets WDG. For more information please visit www.pacificethanol.net.

CONTACT: Company IR Contact:
         Pacific Ethanol, Inc.
         916-403-2755
         866-508-4969
         Investorrelations@pacificethanol.net

         IR Agency Contact:
         Becky Herrick
         LHA
         415-433-3777

         Media Contact:
         Paul Koehler
         Pacific Ethanol, Inc.
         916-403-2790
         paulk@pacificethanol.net

(LPDX) to Present at 25th Annual Piper Jaffray Healthcare Conference

RALEIGH, N.C., Nov. 27, 2013 — LipoScience, Inc. (Nasdaq:LPDX) today announced that Bob Greczyn, Interim President and Chief Executive Officer, and Lucy Martindale, Executive Vice President and Chief Financial Officer, will present at the 25^th Annual Piper Jaffray Healthcare Conference at 11:00 A.M. ET on Wednesday, December 4, 2013, in New York City.

The presentation will be webcast live and can be accessed on the Investor Relations section of the corporate website at http://investor.liposcience.com. For those who are not available to listen to the live broadcast, the webcast will be archived for 90 days.

About LipoScience, Inc.

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company’s first proprietary diagnostic test, the NMR LipoProfile^® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience’s automated clinical analyzer, Vantera^®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.

LipoScience is striving toward the NMR LipoProfile test becoming the preferred choice by physicians for management of cardiovascular disease. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.

CONTACT: Investor Relations
         ICR, Inc.
         Bob Yedid
         Senior Vice President
         646-277-1250
         bob.yedid@icrinc.com

         LipoScience, Inc.
         Tori Hall
         tori.hall@liposcience.com
         (919) 256-1046

(AZC) Announces Completion and Availability of Rosemont Final EIS

Augusta Resource Corporation
Letitia Cornacchia, Vice President,
Investor Relations and Corporate Communications
Tel: (416) 860 6310
Email: lcornacchia@augustaresource.com

(SMSI) Regains Compliance With NASDAQ Minimum Bid Price Rule

(UBIC) Masami Yaguchi Named CFO, CAO

Former CFO and CAO, Seitaro Ishii, Transitions to Senior Strategic Advisor

TOKYO, Nov. 26, 2013 — UBIC, Inc. (Nasdaq:UBIC) (TSE:2158), a leading provider of Asian-language eDiscovery solutions and services, today announced that Masami Yaguchi, currently the company’s Controller, will assume the joint position of Chief Financial Officer (CFO) and Chief Administrative Officer (CAO), effective Dec. 1.

Mr. Yaguchi replaces Seitaro Ishii as CFO and CAO who, after assisting in expanding the company’s presence in Asia, North America and Europe and helping to guide it through a successful listing on the Nasdaq Stock Market, will decrease his day-to-day responsibilities to spend more time with his family. A member of UBIC’s senior management team since he joined the company in 2010, Mr. Ishii will continue as a strategic advisor to Chief Executive Officer Masahiro Morimoto and Mr. Yaguchi. He will also remain a member of the board of directors of UBIC’s North American subsidiary.

“It has been my pleasure to work closely with Sam Ishii over the past four years. His leadership and experience were invaluable as the company grew its business and technology, and expanded its presence around the globe,” Mr. Morimoto said. “I am grateful for his help and I am happy Sam will continue as a strategic advisor to me and the senior management team at UBIC.

“UBIC’s new CFO and CAO, Masami Yaguchi, is a talented financial professional. He has demonstrated tremendous capability as Corporate Controller working with our management team over the past year,” Mr. Morimoto said. “His talent, his accomplishments and his familiarity with UBIC make Yaguchi-san a natural choice to succeed Sam Ishii in these key senior management roles.”

Prior to joining UBIC in December, 2012, Masami Yaguchi, 52, served in a variety of management positions in finance and administration including CFO and CAO of a start-up company Springsoft, Inc.; and Finance and Accounting Director for CMA CGM Japan, a world leader in container shipping. He has also worked in various finance roles including operations controller and treasury and tax for Applied Materials Japan, one of the world’s top semiconductor equipment companies.

About UBIC

UBIC, Inc. (TSE:2158) (Nasdaq:UBIC) is a leading provider of Asian-language eDiscovery, forensic solutions and services. UBIC has extensive eDiscovery and forensic experience and expertise with information documented in Japanese, Korean, Chinese as well as English languages, and applies its expertise in connection with cross-border litigation, administrative proceedings and internal investigations, including those related to anti-trust investigations, intellectual property (IP) litigation, the Foreign Corrupt Practices Act (FCPA) and product liability (PL) investigations.

UBIC serves its clients from offices in Japan, the United States, South Korea, Taiwan, Hong Kong and the United Kingdom. UBIC’s proprietary technology platform, Lit i View™, version 6.7, is an innovative eDiscovery solution that accurately handles Asian-language characters, encoding schemes and native file systems. UBIC also recently launched its flexible and customizable Legal Cloud™ service to address the problem of rising costs associated with the growth and dispersion of data volumes across the globe, along with prolonged investigations and litigations.

With flexible, customizable end-to-end solutions and services covering the entire electronic discovery reference model (EDRM) life-cycle for corporate litigation strategy and crisis management, UBIC has assisted clients in more than 310 administrative and legal proceedings in the United States, including Department of Justice (DOJ), International Trade Commission (ITC) and Securities and Exchange Commission (SEC) investigations and more than 700 corporate investigations in Japan, South Korea, China, Taiwan and Singapore. Assisted by highly experienced litigation attorneys, UBIC provides a range of services facilitating fact discovery, patent management, security, internal audit and regulatory compliance that can provide a significant cost savings to its clients.

For more information about UBIC, contact info@ubicna.com or visit http://www.ubicna.com

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the quotations from management in this announcement, as well as UBIC’s strategic and operational plans, contain forward-looking statements. UBIC may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about UBIC’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: UBIC’s goals and strategies; UBIC’s expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, UBIC’s services; UBIC’s expectations regarding keeping and strengthening its relationships with customers; UBIC’s plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where UBIC provides solutions and services. Further information regarding these and other risks is included in UBIC’s reports filed with, or furnished to the Securities and Exchange Commission. UBIC does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and UBIC undertakes no duty to update such information, except as required under applicable law.

CONTACT: Investor Relations Contact:

         UBIC, Inc. (North America)
         Dan Charnas
         Tel: +1 646-308-1561
         Email: ir@ubicna.com

         ICR, Inc.
         Jeremy Peruski
         Tel: +1 646-308-1561
         Email: ir@ubicna.com

(ETAK) to Present at the Sixth Annual LD Micro Conference

OKLAHOMA CITY, Nov. 26, 2013  — Elephant Talk Communications Corp. (NYSE MKT: ETAK), (www.elephanttalk.com), a leading international provider of mobile proprietary Software Defined Network Architecture (Software DNA™) platforms and a market leader in providing cyber security solutions to counter electronic fraud in the cloud, today, announced that Mr. Steven van der Velden, Chief Executive Officer of the Company, will present at the Sixth Annual LD Micro Conference taking place on December 3-5, 2013 in Los Angeles, California.

For those interested in a one-on-one meeting with management, please contact Chris Camarra at (212) 398-3487, or ccamarra@allianceadvisors.net.

About Elephant Talk:
Elephant Talk Communications Corp. (NYSE MKT: ETAK), is a leading international provider of mobile proprietary Software Defined Network Architecture (Software DNA™) platforms for the telecommunications industry that empower Mobile Network Operators (MNOs) and Mobile Virtual Network Operators (MVNOs), Enablers (MVNEs) and Aggregators (MVNAs) with a full suite of applications, Full OSS/BSS Systems, Delivery Platforms, Support and Managed Services, on-site, cloud, hybrid and S/PaaS solutions, including Network, Mobile Internet ID Solutions, Secure Remote Access Management, Loyalty Management and Transaction Processing Services, superior Industry Expertise and high quality Customer Service without substantial upfront investment. Elephant Talk counts several of the world’s leading Mobile Operators amongst its customers, including Vodafone, T-Mobile, Zain and Iusacell. Virtually all business is focused on tier 1 and tier 2 operators worldwide. Visit: www.elephanttalk.com.

Forward-Looking Statements
Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Additional information concerning certain risks and uncertainties that could cause actual results to differ materially from that projected or suggested is contained in the Company’s filings with the Securities and Exchange Commission (SEC), copies of which are available from the SEC or may be obtained upon request from the Company.

Media Contacts:

Investor Relations:
Steve Gersten
Elephant Talk Communications Corp.
+ 1 813 926 8920
steve.gersten@elephanttalk.com

Thomas Walsh
Alliance Advisors
+ 1 212 398 3486
twalsh@allianceadvisors.net

Public Relations:
US: Michael Glickman
MWG CO
(917) 596.1883
mike@mwco.net

(ECTE) Announces Positive CE Mark Regulatory Trial Results of Symphony® CGM System

Symphony meets primary safety and effectiveness endpoints Company on target to file CE Mark Technical File by year end

PHILADELPHIA, Nov. 26, 2013  — Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony^® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced positive results from its multi-center clinical trial of the Symphony CGM System in surgical patients in hospital critical care units.  Data collected from this study will serve as the basis for the CE Mark Technical File submission for marketing approval in Europe, which the Company expects to submit in the fourth quarter of 2013.

Symphony met the primary safety and effectiveness endpoints of the trial which involved the continuous monitoring of glucose levels in 32 subjects in the critical care units at four investigational sites.  In the trial, Symphony monitored glucose levels with a mean absolute relative difference (MARD), or error rate, of 12.5%.  The Continuous Glucose-Error Grid Analysis (CG-EGA) showed that 97.9% of the readings were clinically accurate (A) and 1.8% were benign (B) errors with a combined A+B categorization of 99.7%.

“We are extremely pleased with the positive results of this trial. Importantly, this was the largest study of Symphony to date and it was the first time that all of the components of the system were used together in a clinical trial. We believe Symphony demonstrated satisfactory safety, accuracy and reliability during the clinical trial to satisfy CE Mark requirements,” said Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics.  “We believe that there is great clinical need in the hospital for a non-invasive continuous glucose monitoring system, like Symphony, to support glycemic control protocols in hospital critical care units, leading to improved clinical outcomes.”

Study Results

Using over 630 Symphony CGM glucose readings paired with reference blood glucose measurements in thirty-two (32) study subjects, CG-EGA showed that 97.9% of the readings were clinically accurate and 1.8% were benign errors, with a combined A+B value of 99.7%.  The MARD for the study was 12.5%.  There were no adverse events reported from the skin preparation or the Symphony CGM sensor session.  The range of glucose values was 49 – 324 mg/dL.

Trial Design

This trial was designed to evaluate the performance of Echo’s Symphony CGM System in thirty-two (32) post-surgical patients in the critical care setting at four investigational sites. Three enrolled patients who were administered an IV formulation of acetaminophen were subsequently excluded from the study based on an observed interference with the glucose sensor. The skin of each patient was prepared using the skin preparation device, and a Symphony CGM sensor was then applied to the prepared site.  During the 24-hour study period, a maximum of thirty reference blood samples were taken from arterial line catheters and measured on a YSI 2300 STAT Plus Glucose Analyzer as a reference.  The data collected by Symphony was blinded to study subjects and investigational institution clinical staff.  At the conclusion of the study period, the prepared skin sites were inspected for redness or other undesirable effects immediately following sensor removal, and again 7 days after sensor removal.

Analytical Methods

Continuous data from the Symphony CGM System were compared to reference measurements from the YSI 2300 STAT Plus Glucose Analyzer. Those reference measurements were paired with the Symphony results through a data analysis algorithm. Data from the three subjects with the observed IV acetaminophen interference were excluded from the analysis, as these subjects were not considered evaluable due to the interference issue. The primary statistical analytical tools used to evaluate the performance of Symphony were MARD and CG-EGA. Numerical accuracy is measured using MARD, an error calculation tool that was used to measure the absolute value of the average relative difference between Symphony and the reference measurements, on a percentage basis. The CG-EGA is a categorization of all data pairs based on the clinical significance of the accuracy.  Accurate readings result in the same clinical decision when based on the CGM value versus the blood glucose value.  Benign errors lead to the same clinical outcome as accurate readings even though the actual clinical decision may differ.  Erroneous readings lead to clinical errors.  CGM performance is measured as the sum of accurate readings and benign errors.

Safety was assessed using a five point dermatological scale immediately after sensor removal and again seven days post sensor removal.

Conference Call

Management will host a conference call today starting at 9:00 AM ET to discuss the trial results and other recent developments.  To listen in and/or participate in the call, please dial (877) 300-8521 and reference Echo Therapeutics’ call.  The archived audiocast will be available for fourteen days following the call by visiting the Events section of Echo’s website at www.echotx.com.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the hospital critical care setting. Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting. The Prelude^® SkinPrep System, a component of the Symphony CGM System, allows for enhanced skin permeation that will enable extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, including those regarding Echo’s submission of a CE Mark Technical File for marketing approval in Europe, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s ongoing studies, including the safety and efficacy of Echo’s Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo’s Symphony CGM System, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com

Connect With Us:
– Visit our website at www.echotx.com
– Follow us on Twitter at www.twitter.com/echotx
– Join us on Facebook at www.facebook.com/echotx

(MBIS) Announces Strategic Investment and Alliance With 3DPrintingIndustry.com

Mediabistro Inc. (Nasdaq:MBIS) today announced that it has made a strategic investment in the 3D printing media platform http://3dprintingindustry.com (3DPI). Mediabistro will not have editorial control of the content of the 3DPI portfolio, which will remain independent, but the two companies will work together to produce Inside 3D Printing trade shows along with the recently announced Maker Summit & Pavilion series that are being produced in major cities worldwide. In addition both companies will soon offer the first online job board for the 3D printing industry, powered by Mediabistro’s proprietary job board software.

“We are pleased to be associated with what we believe to be the most widely read media platform that is fully dedicated to the 3D printing industry and community,” stated Alan M. Meckler, Chairman and CEO of Mediabistro Inc. “Ari Honka and Eetu Kuneinen, the founders of 3DPI, together with Rachel Park, the site’s Editor in Chief, and their superior writing team provide extensive and in-depth daily coverage of all aspects of the growing 3D printing industry worldwide. Also, Mediabistro has the largest coverage of international trade shows for the 3D printing industry combined with coverage of the Maker community. This partnership will enhance marketing dissemination of information and marketing efforts for both companies going forward.”

Ari Honka, Co-founder of 3DPI commented: “As we continue to build 3dprintingindustry.com into the leading multi-media platform for serving the 3D printing sector we are delighted to be working with such a distinguished and experienced partner as Mediabistro. This collaboration offers a strategic fit for several new business areas we are developing at 3DPI — way beyond the investment itself. Both companies have a strong footing in this fast growing industry and we look forward to working closely with Mediabistro to build a truly global presence across a variety of media channels.”

For more information, visit http://inside3dprinting.com.

If your company is interested in sponsoring or exhibiting, contact us at 3dprinting.sponsors@mediabistro.com.

About Mediabistro Inc.

Mediabistro Inc. (Nasdaq: MBIS) is a leading Internet media company that provides services for social media, traditional media, and creative professionals, as well as for innovators in the 3D printing and mobile app industries. Service offerings include an online job board, news and analysis, trade shows and events, online and in-person courses, and research products.

All current Mediabistro Inc. press releases can be found online at:
http://corporate.mediabistro.com/corporate/press.html

About 3dprintingindustry.com

3D Printing Industry (3DPI) is a global media company providing dedicated resources for anyone interested in 3D printing — a technology field that is growing quickly in relevance and application across industrial and consumer sectors. The mission of 3DPI is to report on the latest developments in 3D printing to keep our large and growing audience abreast of technology breakthroughs, the latest applications and the opinions of industry insiders. 3DPI provides a compelling blend of articles, blog posts and opinions, as well as videos and images across all platforms through our main website and social media sites. The company is also developing a series of industry leading reports for the market, in collaboration with Econolyst.

(CYTR) to Present at the Sixth Annual LD MICRO “Main Event” Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A. Kriegsman and Vice President of Business Development David J. Haen will present at the 6^th Annual LD MICRO “Main Event” Conference on Tuesday, December 3^rd, 2013 at 4:00 p.m. Pacific time. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles.

Mr. Kriegsman and Mr. Haen will be available for one-on-one meetings with the investment community on Tuesday, December 3^rd. Please contact LD Micro organizers if you would like to arrange a meeting.

Interested parties can access the audio webcast with slide presentation at http://www.cytrx.com/investors/presentations. An archived presentation will be available for 90 days.

About LD MICRO

LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The firm also hosts the LD MICRO Micro-Cap Growth Conference for investors in December of each year. This year’s conference will feature presentations by over 225 publicly-traded companies and is expected to attract more than 1,000 attendees.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and has completed a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to initiate under a special protocol assessment a potential pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx also has initiated a Phase 2 clinical trial with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and is initiating a Phase 2 clinical trial for AIDS-related Kaposi’s sarcoma. CytRx plans to expand its pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites. CytRx also has rights to two additional drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about CytRx Corporation, visit www.cytrx.com.

(HTBX) Completes HS-410 Manufacturing For Phase 1/2 Bladder Cancer Trial Start

Company Remains on Track to Commence Patient Enrollment in Phase 1/2 Trial Before Year End

Company Remains on Track to Commence Patient Enrollment in Phase 1/2 Trial Before Year End

(IDIX) to Present at Two Upcoming Healthcare Conferences

CAMBRIDGE, Mass., Nov. 25, 2013  — Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will participate in a fireside chat discussion at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013, at 10:45 a.m. ET at the Four Seasons Hotel in Boston, MA. Management will also present a corporate overview at the Oppenheimer 24th Annual Healthcare Conference on Tuesday, December 10, 2013, at 4:30 p.m. ET at the Crowne Plaza Hotel in New York, NY.

The live and archived webcasts of the company presentations can be accessed under “Events and Presentations” in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conferences.

ABOUT IDENIX

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical Company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix’s current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.

CONTACT: Idenix Pharmaceuticals Contact:
         Teri Dahlman
         (617) 995-9807

(TGTX) Initiates First Combination Clinical Trial of TG-1101 and TGR-1202

• Combination trial led by Susan O’Brien, MD and Nathan Fowler, MD from the MD Anderson Cancer Center in Houston, Texas
• Nodal responses observed at 800mg once per day; Company initiates first expansion cohort of TGR-1202 as a single agent while dose escalation continues

NEW YORK, Nov. 25, 2013  — TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that it has initiated a multi-center, Phase I trial to evaluate the safety and efficacy of the combination of TG-1101 (ublituximab) and TGR-1202 for patients with relapsed and/or refractory Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin’s Lymphoma (NHL). This will be the first clinical trial evaluating the combination of TG-1101, the Company’s novel glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, the Company’s novel, once per day, PI3K Delta inhibitor. In this study, dosing of TGR-1202 will commence at 800mg once per day (or QD) with dose escalation proceeding in a 3+3 design.

The trial, entitled “A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of TG-1101 (Ublituximab), a novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Novel PI3k Delta Inhibitor, in Patients with B-cell Malignancies,” will enroll CLL and NHL patients whose disease is relapsed from or refractory to prior therapies, including prior anti-CD20 monoclonal antibodies, PI3K Delta inhibitors, and/or BTK inhibitors. The MD Anderson Cancer Center will be the lead center for the trial. Susan O’Brien, MD, Professor in the Department of Leukemia, will be the Study Chair for the CLL patient group, and Nathan Fowler, MD, Assistant Professor and Co-Director of Clinical Research in the Department of Lymphoma, will be the Study Chair for the NHL patient group.

In addition, TG Therapeutics announced today that it has opened its first expansion cohort in its ongoing single agent Phase 1 dose escalation study of TGR-1202. The expansion cohort will enroll additional patients at the 800mg QD dose level. As a maximum tolerated dose has not been reached, dose escalation continues in this study. To date, the Company has not observed any TGR-1202 drug-related liver toxicity. At the upcoming American Society of Hematology Meeting (ASH) in December 2013, the Company intends to present detailed pharmacokinetic and safety data for all patients in the ongoing single agent study of TGR-1202 through the 1200mg QD cohort as well as efficacy data through the 800mg QD dose escalation cohort (Abstract 4373 which can be found at https://ash.confex.com/ash/2013/webprogram/Paper61825.html).

“With the confirmation of activity of TGR-1202, we are one step closer to fulfilling our vision of bringing highly active, less toxic, non-chemotherapy based combination treatment options to patients with B-cell malignancies,” stated Michael S. Weiss, Executive Chairman and Interim CEO, who continued, “The commencement of this combination study today represents a major milestone for the Company and is the beginning of what we expect to be a robust combination clinical program, which will include our much anticipated combination of TG-1101 with ibrutinib. We are very excited to have MD Anderson as our lead center and to be working with Dr. O’Brien and Dr. Fowler, as co-lead investigators for this important clinical trial.”

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor, jointly with Rhizen Pharmaceuticals S A. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that pre-clinical and early clinical results that supported our decision to move forward with TG-1101 and TGR-1202 will not be reproduced in additional patients or in future studies; the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following completion of the current phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX-G

CONTACT: Jenna Bosco
         Director- Investor Relations
         TG Therapeutics, Inc.
         Telephone: 212.554.4484
         Email: ir@tgtxinc.com

(OREX) Announces Successful Interim Analysis of Contrave Light Study

Company will Resubmit the Contrave NDA in the Next Few Weeks – Potential Approval by June 2014

SAN DIEGO, Nov. 25, 2013 — Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced successful results of the interim analysis of the Light Study. Based on these results, the Company will resubmit the Contrave® New Drug Application (NDA) to the United States Food and Drug Administration (FDA) in the next few weeks with potential approval by June 2014.

“The interim analysis of the Light Study clearly achieved the goal set by the FDA,” said Michael Narachi, CEO of Orexigen.  “The resubmission will contain an unprecedented amount of cardiovascular outcomes data for an obesity therapeutic, and we are confident these data will support a favorable benefit:risk assessment for Contrave.”

The FDA previously agreed that if the interim analysis meets the specified criteria to exclude cardiovascular risk, Contrave could be approved. The pre-specified criteria for the interim analysis is to exclude a hazard ratio of 2.0, using the upper bound of the 95% confidence interval, for excess risk of major adverse cardiovascular events (MACE) in patients receiving Contrave as compared to placebo. In addition to meeting the pre-specified criteria for excluding cardiovascular risk, no new safety signals were observed.

“Takeda is excited about this major milestone for Contrave,” said Doug Cole, President of Takeda Pharmaceuticals U.S.A., Inc., Orexigen’s partner for Contrave in North America. “Takeda is pleased to partner with Orexigen to develop a therapeutic option that has the potential to help patients achieve meaningful and sustained weight loss over time.”

Conference Call This Morning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)

The Orexigen management team will host a teleconference and webcast to discuss the interim analysis results. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36202424. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About the Light Study

The Contrave Light Study is a double‐blind, placebo‐controlled cardiovascular outcomes trial that randomized approximately 8,900 patients.  The primary objective of the Light Study, which Orexigen is conducting under a Special Protocol Assessment with the FDA at approximately 260 clinical sites in the United States, is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave.

By agreement with the FDA, the independent Data Monitoring Committee’s summary report of the Light Study interim analysis will form the basis of the resubmission of the NDA, and the complete clinical study report (CSR) for the interim analysis, which would ordinarily form the basis for the NDA resubmission filing, will be supplied to the FDA during its review within 60 days of the NDA resubmission.

Following potential approval in June 2014, the Light Study will continue, blinded, until the trial is completed.

About Contrave
Contrave (naltrexone sustained release (SR)/bupropion SR) is an investigational medication being evaluated for weight loss. Prior to initiation of the Light Study, Contrave was studied in clinical trials enrolling more than 4,500 people. Contrave has been shown to help people lose weight and keep it off for up to one year. In previous clinical trials, 53 percent of study participants taking Contrave and 21 percent of those taking placebo lost five percent or more of their body weight over the 12 month trial duration. Many patients saw noticeable improvements in cholesterol levels, and blood sugar control, as well as smaller waistlines. Those who combined Contrave with diet and exercise experienced the most reduction in body weight. There is no guarantee that Contrave will make patients lose weight.

Contrave was generally well tolerated in earlier clinical trials. In the Contrave Phase 3 clinical development program, the most frequent adverse events on Contrave were nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea. These were mostly mild to moderate in severity and did not last long.

Orexigen has licensed North American Contrave rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights in Europe and throughout the rest of the world outside of North America and will seek a partner to commercialize Contrave in those territories. In October 2013, Orexigen submitted a Marketing Authorization Application (MAA) for Contrave to the European Medicines Agency (EMA).

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application had been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company’s other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward‐Looking Statements
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward‐looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company’s current beliefs and expectations. These forward‐looking statements include statements regarding: the timing of resubmission and potential approval of the NDA for Contrave; the benefit risk profile for Contrave; Orexigen’s plans to seek a commercialization partner in territories outside of North America; and the timing of the submission of the CSR for the interim analysis. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: delays in the resubmission of the Contrave NDA; the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the CSR for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; the potential for the FDA to not approve Contrave even after meeting the prespecified threshold and resubmitting the NDA; the possibility that public disclosure of the results of the interim analysis would later be deemed to jeopardize the integrity of the Light Study potentially resulting in the requirement to conduct additional, costly studies; additional analysis of the interim results or new data from the continuing Light Study, including safety-related data, may produce negative or inconclusive results, or may be inconsistent with the conclusion that the interim analysis was successful; the potential that the interim analysis may not be predictive of future results in the Light Study; the potential for early termination of Orexigen’s North American collaboration agreement with Takeda Pharmaceutical Company Limited; the results from the interim analysis may not sufficient to satisfy or respond to the Day 120 List of Questions from the EMA or any other data requirements of the EMA in connection with the review of the MAA; even if the NDA is approved by the FDA, the final results of the Light Study may not support continued approval of Contrave; the therapeutic and commercial value of Contrave; Orexigen’s ability to maintain sufficient capital to fund its operations through potential approval of Contrave in 2014; and other risks described in Orexigen’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in Orexigen’s Quarterly Report on Form 10‐Q filed with the Securities and Exchange Commission November 12, 2013 and its other reports, which are available from the SEC’s website (www.sec.gov) and on Orexigen’s website (www.orexigen.com) under the heading “Investor Relations.” All forward‐looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

(AEZS) Announces Closing of US$15.1 Million Public Offering of Common Shares and Warrants

Investor Relations
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265
gvallieres@aezsinc.com

Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
pburroughs@aezsinc.com

(IDRA) to Present at the 25th Annual Piper Jaffray Healthcare Conference

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 3:00 p.m. EST at the New York Palace Hotel in New York City.

A live audio webcast of the presentation will be available in the Investors and Media section of Idera’s website at www.iderapharma.com or at the link http://www.media-server.com/m/p/c8zsyhqf. An archived version will also be available on the Company’s website after the event for 90 days.

About Idera Pharmaceuticals, Inc.

Idera’s technology platform involves creating novel synthetic RNA- and DNA-based compounds to modulate immune responses. Idera has applied this platform to develop proprietary Toll-like receptor (TLR) antagonists as immunomodulatory drug candidates. Toll-like receptor antagonists block the over-activation of immune factors which can cause a range of pathological effects. Idera is conducting clinical development of TLR antagonists in autoimmune and inflammatory diseases, and preclinical development of their use in certain genetically defined forms of B-cell lymphoma. More information on Idera is available at www.iderapharma.com.

(CTHR) Forever Brilliant® Moissanite Collection Now Available at Helzberg.com

Partnership Targeted to Provide Sales Opportunity and Increase Awareness for The World’s Most Brilliant Gem

Charles & Colvard, Ltd. (NASDAQ:CTHR), the exclusive global supplier of the Forever Brilliant^® moissanite gem, has entered into a distribution agreement with Helzberg Diamonds, a Berkshire Hathaway Company and one of the oldest and largest retail and online jewelry stores, to directly supply Forever Brilliant^® moissanite fine jewelry in 14-karat gold to the retailer’s e-commerce site.

“We are excited to announce our partnership with one of the largest U.S. jewelry retailers, Helzberg Diamonds, especially as Charles & Colvard’s continues to expand channel offerings and increase consumer awareness of moissanite in time for the all-important holiday season,” said Randy N. McCullough, CEO at Charles & Colvard. “For more than 90 years, Helzberg has provided customers with superior service and high-quality jewelry, and the availability of Forever Brilliant^® moissanite in their online store is a testament to the growing excitement for our proprietary gemstone.”

“We are very pleased to bring Forever Brilliant^® moissanite jewelry to Helzberg’s online customers, said Steve Larkin, COO of Charles & Colvard. This partnership between Charles & Colvard and Helzberg is designed to increase consumer access to moissanite. We believe this is the perfect opportunity to build awareness of our finest brand of moissanite, Forever Brilliant^®. We look forward to bringing our proprietary Forever Brilliant gem to the many Helzberg consumers and satisfying their demand for beautiful 14-karat gold Forever Brilliant^® moissanite stud earrings, solitaire rings, bridal, and fashion fine jewelry through Helzberg’s online store.”

More information about the entire Charles & Colvard moissanite line is available at www.charlesandcolvard.com.

About Helzberg Diamonds:

Helzberg Diamonds was founded over 90 years ago, and since day one we’ve dedicated ourselves to delighting our customers with superior service and high-quality jewelry. That’s because we understand how special it is to buy fine jewelry – and we want you to treasure the experience for years to come. For more information, please visit www.helzberg.com.

About Charles & Colvard:

Charles & Colvard, Ltd., based in the Research Triangle Park area of North Carolina, is the global sole source of moissanite, a unique, near-colorless created gemstone that is distinct from other gemstones and jewels based on its exceptional fire, brilliance, luster, durability, and rarity. Charles & Colvard Created Moissanite^® and Forever Brilliant^® are currently incorporated into fine jewelry sold through domestic and international retailers and other sales channels. Charles & Colvard, Ltd.’s common stock is listed on the NASDAQ Global Select Market under the symbol “CTHR.” For more information, please visit www.charlesandcolvard.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements expressing expectations regarding our future and projections relating to products, sales, revenues, and earnings are typical of such statements and are made under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations, and contentions and are not historical facts and typically are identified by use of terms such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “continue,” and similar words, although some forward-looking statements are expressed differently.

All forward-looking statements are subject to the risks and uncertainties inherent in predicting the future. You should be aware that although the forward-looking statements included herein represent management’s current judgment and expectations, our actual results may differ materially from those projected, stated, or implied in these forward-looking statements as a result of many factors including, but not limited to, our dependence on consumer acceptance and growth of sales of our products resulting from our strategic initiatives; dependence on a limited number of customers; our ability to fulfill orders on a timely basis; the financial condition of our major customers; dependence on Cree, Inc. as the sole current supplier of the raw material; our current wholesale customers’ potential perception of us as a competitor in the finished jewelry business; intense competition in the worldwide jewelry industry; general economic and market conditions, including the current economic environment; risks of conducting business in foreign countries; the pricing of precious metals, which is beyond our control; the potential impact of seasonality on our business; our ability to protect our intellectual property; the risk of a failure of our information technology infrastructure to protect confidential information and prevent security breaches; possible adverse effects of governmental regulation and oversight; and the failure to evaluate and integrate strategic opportunities, in addition to the other risks and uncertainties described in our filings with the Securities and Exchange Commission, or the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and subsequent reports filed with the SEC. Forward-looking statements speak only as of the date they are made. We undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur except as required by the federal securities laws, and you are urged to review and consider disclosures that we make in the reports that we file with the SEC that discuss other factors relevant to our business.

(LFVN) CSO David Phelps Sees “Extraordinary Growth Potential”

SALT LAKE CITY, Nov. 22, 2013 — LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically-validated products, introduced David Phelps as its first-ever Chief Sales Officer on Tuesday, and already Phelps is speaking out.

“LifeVantage has extraordinary growth potential,” Phelps said. “The current product line has fueled impressive growth since the company entered into network marketing in 2009, but I believe that is just our taking-off point.”

Phelps continued, “We’re expanding our U.S. market, preparing to launch our flagship product, Protandim^®, the Nrf2 Synergizer^® patented dietary supplement, in a number of major new markets worldwide and gearing up to announce exciting new products, all in keeping with our commitment to offer unique science-based formulations for healthy living.”

“Our approximately 70,000 independent distributors have their eyes on a prize,” added Phelps, “and that’s making LifeVantage a billion-dollar company. They know we have the products and sales know-how to do that. I just spent 24 hours with the company’s top 19 global distributors at a summit in Utah. These are some of the most determined, passionate, experienced and insightful network marketers I have ever met. Their conviction and energy, combined with the work of the smart, hard-charging LifeVantage management team, enhances our growth potential.” Phelps also noted, “I am truly impressed with the entire leadership team’s unity in creating the next wave of LifeVantage momentum.”

A globally recognized expert in network marketing, Phelps’s experience spans North America, Europe, Latin America and nearly every major market in Asia. He has worked at Synergy Worldwide, FFi, Jeunesse Global, MonaVie and Organo Gold, applying his skills in sales, marketing, international expansion, business development, training and nearly every facet of distributor-facing development work. Phelps received his Juris Doctorate from Brigham Young University.

Douglas C. Robinson, LifeVantage President and Chief Executive Officer, noted, “Like the rest of the LifeVantage management team, Dave is driven by two essential concepts: Distributors are the company’s most important assets, and leadership development is the heart of our network marketing success. LifeVantage is ready to surge to new heights, and we are excited to have Dave Phelps join the team that will help take us there.”

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq:LFVN), a leader in Nrf2 science and the maker of Protandim®, the Nrf2 Synergizer® patented dietary supplement, TrueScience® Anti-Aging Cream and LifeVantage® Canine Health, is a science-based network marketing company. LifeVantage is dedicated to visionary science that looks to transform wellness and anti-aging internally and externally with products that dramatically reduce oxidative stress at the cellular level. The Company was founded in 2003 and is headquartered in Salt Lake City, Utah. More information is available at www.LifeVantage.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism and satisfaction with current prospects, as well as words such as “believe,” “anticipates,” “look forward to,” “should” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding the Company’s growth potential are not guarantees of performance and the Company’s actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others the risk factors discussed in greater detail in the Company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption “Risk Factors,” and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

CONTACT: Public Relations Contact:
         John Genna (801) 432-9172
         Vice President of Marketing & Communications

         Investor Relations Contact:
         Cindy England (801) 432-9036
         Director of Investor Relations
         or
         John Mills (310) 954-1105
         Senior Managing Director, ICR, LLC